{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:01Z","timestamp":1786121161978,"version":"build-2736575974"},"reference-count":152,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017585","name":"First Hospital of Jilin University","doi-asserted-by":"publisher","award":["JDYY14202313"],"award-info":[{"award-number":["JDYY14202313"]}],"id":[{"id":"10.13039\/501100017585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hbpd.2025.12.008","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:49:23Z","timestamp":1765471763000},"page":"362-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights"],"prefix":"10.1016","volume":"25","author":[{"given":"Cheng","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ji","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2025.12.008_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0002","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0003","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0004","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.bjc.6601140","article-title":"A meta-analysis of obesity and the risk of pancreatic cancer","volume":"89","author":"Berrington de Gonzalez","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ijc.2910510306","article-title":"A collaborative case-control study of nutrient intake and pancreatic cancer within the search programme","volume":"51","author":"Howe","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0007","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.1158\/0008-5472.CAN-06-0494","article-title":"High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL","volume":"66","author":"Goldstein","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0008","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0009","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.seminoncol.2016.09.002","article-title":"Familial pancreatic cancer","volume":"43","author":"Petersen","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0012","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0013","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0014","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.pmbts.2016.09.006","article-title":"Current and emerging targeting strategies for treatment of pancreatic cancer","volume":"144","author":"Baines","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0016","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0017","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0018","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0019","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making Cold tumors Hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rmed.2011.10.015","article-title":"Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies","volume":"106","author":"Stella","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0021","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","article-title":"A phase I\/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer","volume":"26","author":"Pishvaian","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0022","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","article-title":"Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0024","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0025","article-title":"Advancements in systemic therapy for pancreatic cancer","volume":"43","author":"Brown","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0026","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0027","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for Germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0028","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","article-title":"A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer","volume":"40","author":"Tuli","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0029","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0030","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0031","first-page":"1884","article-title":"Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience","volume":"40","author":"Takeda","year":"2013","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0032","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10238-016-0409-2","article-title":"Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts","volume":"17","author":"Tai","year":"2017","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0033","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdp496","article-title":"Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts","volume":"21","author":"Larbouret","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0034","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1535-7163.MCT-14-0485","article-title":"A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR\/Src\/VEGFR2, as a therapeutic agent against pancreatic cancer","volume":"14","author":"Pan","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0035","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.3390\/ijms24065422","article-title":"Anticancer activity of sunitinib analogues in human pancreatic cancer cell cultures under normoxia and hypoxia","volume":"24","author":"Skarait\u0117","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0036","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2014.10.010","article-title":"A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV","volume":"51","author":"Bergmann","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0037","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10637-018-0639-0","article-title":"Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial","volume":"37","author":"Dittrich","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0038","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114067","article-title":"Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer","volume":"178","author":"Booth","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrgastro.2013.234","article-title":"Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer","volume":"11","author":"Saif","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0041","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2014.12.027","article-title":"Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer","volume":"358","author":"Awasthi","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0042","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"106","author":"Harder","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0043","doi-asserted-by":"crossref","first-page":"12796","DOI":"10.18632\/oncotarget.3473","article-title":"Dual targeting of HER1\/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the \u201cTHERAPY\u201d phase 1-2 trial","volume":"6","author":"Assenat","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0044","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.33225","article-title":"Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)","volume":"148","author":"Assenat","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0046","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0047","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0048","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0049","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: swog S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon-2017-0338","article-title":"HALO-109-301: a phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer","volume":"14","author":"Doherty","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00124","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study","volume":"3","author":"Al Baghdadi","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0052","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1002\/cam4.2425","article-title":"A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer","volume":"8","author":"Hu","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0053","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","volume":"30","author":"Tolcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0054","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10637-014-0083-8","article-title":"A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma","volume":"32","author":"De Jesus-Acosta","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","article-title":"Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours","volume":"125","author":"Rodon","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0056","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2017-0665","article-title":"A phase Ib\/II study of the JAK1 inhibitor, itacitinib, plus nab-paclitaxel and gemcitabine in advanced solid tumors","volume":"24","author":"Beatty","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0057","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1021\/acs.jproteome.0c00587","article-title":"Mutation-specific and common phosphotyrosine signatures of KRAS G12D and G13D alleles","volume":"20","author":"Tahir","year":"2021","journal-title":"J Proteome Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0058","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0059","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/gutjnl-2020-321217","article-title":"Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions","volume":"70","author":"Fujikura","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0060","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1158\/1538-7445.AM2023-5735","article-title":"Abstract 5735: novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models","volume":"83","author":"Nagashima","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0061","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s10020-024-00972-y","article-title":"MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis","volume":"30","author":"Xu","year":"2024","journal-title":"Mol Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0062","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1038\/s41388-024-03196-w","article-title":"KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56\u03b1 to initiate pancreatic cancer development","volume":"43","author":"Tinsley","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0063","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.201900236","article-title":"Advances in targeted therapy and immunotherapy for pancreatic cancer","volume":"5","author":"Liu","year":"2021","journal-title":"Adv Biol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-025-02288-9","article-title":"ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma","volume":"24","author":"Bandi","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0066","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0067","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0068","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/hmg\/10.7.705","article-title":"BRCA1 and BRCA2 and the genetics of breast and ovarian cancer","volume":"10","author":"Welcsh","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0069","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/14656566.2020.1837113","article-title":"An evaluation of olaparib for the treatment of pancreatic cancer","volume":"22","author":"Vaishampayan","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0071","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0072","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1017\/erm.2021.26","article-title":"Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer","volume":"23","author":"Cao","year":"2021","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0073","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0074","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000502844","article-title":"Cetuximab in pancreatic cancer therapy: a systematic review and meta-analysis","volume":"98","author":"Forster","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0076","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12885-019-5322-0","article-title":"VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer","volume":"19","author":"Lian","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0077","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0078","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdm408","article-title":"A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities","volume":"18","author":"Christensen","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0080","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ccell.2016.02.010","article-title":"Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2","volume":"29","author":"Foster","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0081","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/01.pas.0000160979.85457.73","article-title":"Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival","volume":"29","author":"Saxby","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0082","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1081\/CNV-200032974","article-title":"Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2\/neu","volume":"22","author":"Safran","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0083","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/curroncol28010053","article-title":"Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults","volume":"28","author":"Bebb","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0084","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0085","volume":"6","author":"Delgado","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0086","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0087","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future","volume":"21","author":"Christenson","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0088","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1053\/j.gastro.2016.03.040","article-title":"Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma","volume":"150","author":"DuFort","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0089","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0090","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1535-7163.MCT-15-0764","article-title":"SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts","volume":"15","author":"Kim","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0091","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2326-6066.CIR-16-0125","article-title":"Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer","volume":"5","author":"Cullis","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0092","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.gastro.2024.02.046","article-title":"Targeting ESE3\/EHF with nifurtimox inhibits CXCR2+ neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy","volume":"167","author":"Xie","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0093","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the Hedgehog signaling pathway in cancer: a comprehensive review","volume":"18","author":"Skoda","year":"2018","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0094","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature02009","article-title":"Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis","volume":"425","author":"Thayer","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0095","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/MPA.0000000000001888","article-title":"The role of inherited pathogenic CDKN2A variants in susceptibility to pancreatic cancer","volume":"50","author":"Kimura","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0096","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-18-4192","article-title":"Dissecting the stromal signaling and regulation of myeloid cells and memory effector T cells in pancreatic cancer","volume":"25","author":"Blair","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0097","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0098","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0099","first-page":"2995","article-title":"A novel p16INK4A transcript","volume":"55","author":"Mao","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0100","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/366704a0","article-title":"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4","volume":"366","author":"Serrano","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0101","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0102","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0103","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.18632\/oncotarget.2270","article-title":"CDK4\/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer","volume":"5","author":"Franco","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0104","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0105","first-page":"98","article-title":"Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling","volume":"54","author":"Sun","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0106","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.3390\/ijms22094765","article-title":"Pancreatic cancer and therapy: role and regulation of cancer stem cells","volume":"22","author":"Barman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0107","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.3390\/curroncol28050312","article-title":"Activity of the gamma secretase inhibitor AL101 in desmoid tumors: a case report of 2 adult cases","volume":"28","author":"Chan","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0108","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/annonc\/mdy244","article-title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","volume":"29","author":"Massard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0109","doi-asserted-by":"crossref","first-page":"eaau6246","DOI":"10.1126\/scitranslmed.aau6246","article-title":"Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition","volume":"11","author":"Habets","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0110","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2016.71.1994","article-title":"Clinical activity of the \u03b3-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis)","volume":"35","author":"Kummar","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0111","doi-asserted-by":"crossref","first-page":"12649","DOI":"10.1073\/pnas.1307218110","article-title":"Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0112","first-page":"59","article-title":"Updated interpretation of the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024.V3.Edition)","volume":"40","author":"Wang","year":"2025","journal-title":"Chin J Gen Surg"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0113","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0114","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(21)00286-2","article-title":"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial","volume":"22","author":"Zhu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0115","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study","volume":"28","author":"Wang-Gillam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0117","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0118","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0119","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"180","author":"Chen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0120","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0121","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0122","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0123","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","article-title":"Evaluation of cyclophosphamide\/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0124","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF\u2013transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","article-title":"Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study","volume":"17","author":"Hardacre","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (HyperAcute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0127","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10238-011-0159-0","article-title":"A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer","volume":"12","author":"Rong","year":"2012","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0128","first-page":"2217","article-title":"WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study","volume":"38","author":"Yanagisawa","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0129","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1080\/21645515.2021.2003645","article-title":"Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and\/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy","volume":"17","author":"Ota","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2022.03.015","article-title":"Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study","volume":"169","author":"Lau","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0131","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","article-title":"TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial","volume":"122","author":"Palmer","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0132","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","article-title":"T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours","volume":"5","author":"Lesch","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0133","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0134","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0135","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00262-014-1566-3","article-title":"Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer","volume":"63","author":"Chung","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0136","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0137","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0138","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0139","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/gutjnl-2024-333492","article-title":"Induction of macrophage efferocytosis in pancreatic cancer via PI3K\u03b3 inhibition and radiotherapy promotes tumour control","volume":"74","author":"Russell","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0140","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0141","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0142","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.031","article-title":"Trials and tribulations of pancreatic cancer immunotherapy","volume":"504","author":"Principe","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0144","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/sj.bjc.6602232","article-title":"MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate","volume":"91","author":"Qu","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0146","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0147","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0148","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/21645515.2015.1093264","article-title":"Pancreatic cancer: update on immunotherapies and algenpantucel-L","volume":"12","author":"McCormick","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0149","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nbt0817-691","article-title":"First approval in sight for Novartis\u2019 CAR-T therapy after panel vote","volume":"35","author":"Sheridan","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0151","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2017.06.008","article-title":"CXCL16\/CXCR6-mediated adhesion of human peripheral blood mononuclear cells to inflamed endothelium","volume":"122","author":"Linke","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.hbpd.2025.12.008_bib0152","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/gutjnl-2023-330995","article-title":"The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells","volume":"73","author":"L\u00f3pez-Gil","year":"2024","journal-title":"Gut"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149938722500222X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149938722500222X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:27:25Z","timestamp":1786073245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S149938722500222X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S149938722500222X"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2025.12.008","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}